Treatment study for patients with gestational trophoblastic neoplasia (GTN)

What we are studying

The purpose of this study is to compare actinomycin-D and methotrexate to find out which works better to control GTN with the fewest side effects and least interruption in normal daily living. In this study, you will get either the actinomycin-D or methotrexate (and Leucovorin if your doctor prefers to give the methotrexate in your muscle). You will not get both drugs.

Who we are studying

  • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosis of gestational trophoblastic neoplasia (GTN)
  • Willing to practice effective contraception for the duration of the study
  • Have not previously been treated with cytotoxic chemotherapy
  • Have not previously received radiation to the pelvis

What is involved

  • Receive actinomycin-D through an IV once per cycle or a shot of methotrexate every other day for 8 days (4 doses per cycle)
  • Cycles will be repeated every 14 days

Contact Information

Study Coordinator
Melissa Swain, RN
Email
mswain@wakehealth.edu
Phone
336-716-9428

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.